Phase 3 High-Risk Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
High-risk Melanoma
Uppsala University1,792 enrolled26 locationsNCT06488482
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 3
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
High-risk MDS
Gruppo Italiano Malattie EMatologiche dell'Adulto274 enrolled46 locationsNCT04184505
Recruiting
Phase 3
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
High-risk Stage II Colorectal CancerStage III Colorectal CancerCirculating Tumor DNA Methylation
Fudan University340 enrolled1 locationNCT05954078
Recruiting
Phase 3
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Nasopharyngeal CarcinomaHigh-Risk CancerMaintenance Therapy
Jiangxi Provincial Cancer Hospital264 enrolled3 locationsNCT06277050
Recruiting
Phase 3
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Jiangsu HengRui Medicine Co., Ltd.1,256 enrolled1 locationNCT05009290
Completed
Phase 3
Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97)
high-risk operable breast cancer
Hellenic Cooperative Oncology Group600 enrolled1 locationACTRN12611000506998